$CMPX
Compass Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021022412 Filed on April 30, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.635M $2.260M
YoY Change 16.59% -32.54%
% of Gross Profit
Research & Development $4.704M $3.571M
YoY Change 31.73% -50.68%
% of Gross Profit
Depreciation & Amortization $200.0K $500.0K
YoY Change -60.0%
% of Gross Profit
Operating Expenses $7.339M $5.831M
YoY Change 25.86% -44.94%
Operating Profit -$7.339M -$5.831M
YoY Change 25.86%
Interest Expense $142.0K $276.0K
YoY Change -48.55% -284.0%
% of Operating Profit
Other Income/Expense, Net -$83.00K -$555.0K
YoY Change -85.05%
Pretax Income -$7.422M -$6.386M
YoY Change 16.22% -40.54%
Income Tax $0.00 $16.00K
% Of Pretax Income
Net Earnings -$7.422M -$6.402M
YoY Change 15.93% -40.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$144.6K -$122.8K
COMMON SHARES
Basic Shares Outstanding 52.11M 5.000M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.70M
YoY Change
Cash & Equivalents $39.85M $17.79M
Short-Term Investments
Other Short-Term Assets $1.952M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $41.65M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $6.080M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $471.0K
YoY Change
Total Long-Term Assets $6.551M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $41.65M
Total Long-Term Assets $6.551M
Total Assets $48.20M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.061M
YoY Change
Accrued Expenses $1.290M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $7.474M
YoY Change
Total Short-Term Liabilities $10.85M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $3.877M
YoY Change
Total Long-Term Liabilities $3.877M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.85M
Total Long-Term Liabilities $3.877M
Total Liabilities $14.73M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.47M -$124.8M
YoY Change
Total Liabilities & Shareholders Equity $48.20M
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$7.422M -$6.402M
YoY Change 15.93% -40.56%
Depreciation, Depletion And Amortization $200.0K $500.0K
YoY Change -60.0%
Cash From Operating Activities -$5.605M -$7.761M
YoY Change -27.78%
INVESTING ACTIVITIES
Capital Expenditures $128.0K $12.00K
YoY Change 966.67%
Acquisitions
YoY Change
Other Investing Activities $115.0K
YoY Change
Cash From Investing Activities -$13.00K -$12.00K
YoY Change 8.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.875M
YoY Change
NET CHANGE
Cash From Operating Activities -5.605M -7.761M
Cash From Investing Activities -13.00K -12.00K
Cash From Financing Activities -1.875M
Net Change In Cash -7.493M -7.773M
YoY Change -3.6%
FREE CASH FLOW
Cash From Operating Activities -$5.605M -$7.761M
Capital Expenditures $128.0K $12.00K
Free Cash Flow -$5.733M -$7.773M
YoY Change -26.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2020Q4 us-gaap Assets
Assets
51911000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1061000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1290000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1025000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
7474000
CY2021Q1 dei Trading Symbol
TradingSymbol
CMPX
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4892000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7467000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10099000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3877000
CY2020Q4 us-gaap Liabilities
Liabilities
11966000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52081000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52117000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51313000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51221000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4704000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3571000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2635000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2260000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7339000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5831000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7339000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5831000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-555000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7422000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6386000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7422000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6402000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51313000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7122000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
948000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-118603000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
247000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-124758000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7422000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-6402000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
157000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
463000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000
CY2021Q1 cmpx Non Cash Interest Expense
NonCashInterestExpense
15000
CY2020Q1 cmpx Non Cash Interest Expense
NonCashInterestExpense
26000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
948000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
247000
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-320000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
256000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1173000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
34000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-285000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-442000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2072000
CY2021Q1 cmpx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-246000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5605000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7761000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
128000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1875000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1875000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7493000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7773000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25566000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39846000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17793000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
137000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
256000
CY2021Q1 cmpx Noncash Or Part Noncash Acquisition Of Equipment Included In Accrued Expenses
NoncashOrPartNoncashAcquisitionOfEquipmentIncludedInAccruedExpenses
161000
CY2020Q1 cmpx Noncash Or Part Noncash Acquisition Of Equipment Included In Accrued Expenses
NoncashOrPartNoncashAcquisitionOfEquipmentIncludedInAccruedExpenses
15000
CY2020Q1 cmpx Noncash Or Part Noncash Deferred Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredOfferingCostsIncludedInAccruedExpenses
64000
CY2021Q1 cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
5148000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
196000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
326000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2020Q4 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
212000
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-03-20
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
132000000
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15000000
CY2021Q1 cmpx Operating Expenses And Capital Expenditure Period
OperatingExpensesAndCapitalExpenditurePeriod
P12M
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5839000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7061000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4651000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5935000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
365000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
976000
CY2021Q1 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
477000
CY2021Q1 cmpx Long Term Debt Before Unamortized Discount Current
LongTermDebtBeforeUnamortizedDiscountCurrent
7500000
CY2020Q4 cmpx Long Term Debt Before Unamortized Discount Current
LongTermDebtBeforeUnamortizedDiscountCurrent
7500000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
26000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
33000
CY2020Q4 cmpx Long Term Debt Before Unamortized Discount Noncurrent
LongTermDebtBeforeUnamortizedDiscountNoncurrent
1875000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
8000
CY2021Q1 cmpx Number Of Operating Lease
NumberOfOperatingLease
1
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y5M
CY2021Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0625
CY2021Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y2M
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1070000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1315000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1348000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1382000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
426000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5541000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
639000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4902000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
948000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
247000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.58
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7500000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
41000
CY2021Q1 us-gaap Interest Expense
InterestExpense
142000
CY2020Q1 us-gaap Interest Expense
InterestExpense
276000

Files In Submission

Name View Source Status
0001564590-21-022412-index-headers.html Edgar Link pending
0001564590-21-022412-index.html Edgar Link pending
0001564590-21-022412.txt Edgar Link pending
0001564590-21-022412-xbrl.zip Edgar Link pending
cmpx-10q_20210331.htm Edgar Link pending
cmpx-20210331.xml Edgar Link completed
cmpx-20210331.xsd Edgar Link pending
cmpx-20210331_cal.xml Edgar Link unprocessable
cmpx-20210331_def.xml Edgar Link unprocessable
cmpx-20210331_lab.xml Edgar Link unprocessable
cmpx-20210331_pre.xml Edgar Link unprocessable
cmpx-ex311_21.htm Edgar Link pending
cmpx-ex312_22.htm Edgar Link pending
cmpx-ex321_20.htm Edgar Link pending
cmpx-ex322_19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending